Celexa/Lexapro MDL winds up
Celexa/Lexapro MDL winds up
Introduction
The U.S. District Judge Nathaniel M. Gorton granted Forest Laboratories’ motion for summary judgment on all claims made by the plaintiffs who alleged that the company fraudulently promoted Celexa and Lexapro for pediatric depression. This ruling brings an end to the long-running Massachusetts MDL 2067: In Re: Celexa and Lexapro Marketing and Sales Practices Litigation.
Comments
Latest News
Lawyers to Meet Nov. 5 for Talcum Powder Trial Prep
Categories: Talcum
As the first federal talcum powder bellwether trial approaches, both plaintiffs and defendants have finalized their legal teams and are preparing for a key pretrial conference scheduled for early November.
The upcoming proceedings mark a…
2025 Update: What to Know About PPI Lawsuit Settlements & Payout Dates
Categories: Settlements
Last updated on Oct 27, 2025.
The mass tort litigation involving proton pump inhibitor (PPI) drugs — such as Nexium, Prilosec, Prevacid and Protonix — is entering a pivotal phase in …
New Front Emerges in Fight Against Synthetic Opioids
Categories: Opioids
The U.S. opioid crisis has already claimed hundreds of thousands of lives, with fentanyl standing out as one of the deadliest substances. Now the leading cause of death among Americans aged 18 to 44, fentanyl has become synonymous with overdose…